Boothbay Fund Management’s Dermata Therapeutics Warrant DRMAW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.5K | Hold |
12,000
| – | – | ﹤0.01% | 1982 |
|
|
2025
Q4 | $27.8K | Hold |
12,000
| – | – | ﹤0.01% | 1865 |
|
|
2025
Q3 | $60.2K | Hold |
12,000
| – | – | ﹤0.01% | 1771 |
|
|
2025
Q2 | $7.02K | Hold |
12,000
| – | – | ﹤0.01% | 1408 |
|
|
2025
Q1 | $13K | Hold |
12,000
| – | – | ﹤0.01% | 1343 |
|
|
2024
Q4 | $16.2K | Hold |
12,000
| – | – | ﹤0.01% | 1428 |
|
|
2024
Q3 | $19.7K | Hold |
12,000
| – | – | ﹤0.01% | 1550 |
|
|
2024
Q2 | $28.7K | Hold |
12,000
| – | – | ﹤0.01% | 1439 |
|
|
2024
Q1 | $4.93K | Hold |
12,000
| – | – | ﹤0.01% | 1526 |
|
|
2023
Q4 | $7.32K | Hold |
12,000
| – | – | ﹤0.01% | 1606 |
|
|
2023
Q3 | $12.7K | Hold |
12,000
| – | – | ﹤0.01% | 1670 |
|
|
2023
Q2 | $19.8K | Hold |
12,000
| – | – | ﹤0.01% | 1711 |
|
|
2023
Q1 | $15.5K | Hold |
12,000
| – | – | ﹤0.01% | 2067 |
|
|
2022
Q4 | $4.91K | Hold |
12,000
| – | – | ﹤0.01% | 1942 |
|
|
2022
Q3 | $6K | Hold |
12,000
| – | – | ﹤0.01% | 2186 |
|
|
2022
Q2 | $8K | Hold |
12,000
| – | – | ﹤0.01% | 2198 |
|
|
2022
Q1 | $15K | Hold |
12,000
| – | – | ﹤0.01% | 2229 |
|
|
2021
Q4 | $21K | Hold |
12,000
| – | – | ﹤0.01% | 1799 |
|
|
2021
Q3 | $54K | Buy |
+12,000
| New | +$12.3K | ﹤0.01% | 1838 |
|
Other funds holding DRMAW
Boothbay Fund Management's DRMAW Position: Q1 2026 in Review
Boothbay Fund Management held its Dermata Therapeutics Warrant (DRMAW) position steady in Q1 2026 at 12,000 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1982.
Boothbay Fund Management first reported a position in DRMAW in Q3 2021 and has held it in 19 quarters since. The position peaked at $60.2K in Q3 2025. 2 funds tracked by Wall St. Rank hold DRMAW as of Q1 2026.
- Boothbay Fund Management held 12,000 shares of Dermata Therapeutics Warrant worth $14.5K as of Q1 2026.
- Boothbay Fund Management left its Dermata Therapeutics Warrant share count unchanged in Q1 2026.
- Dermata Therapeutics Warrant made up ﹤0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1982 holding.
- Boothbay Fund Management first reported a position in Dermata Therapeutics Warrant in Q3 2021 and has held it in 19 quarters since.
- Boothbay Fund Management's Dermata Therapeutics Warrant position peaked at $60.2K in Q3 2025.
- 2 funds tracked by Wall St. Rank held Dermata Therapeutics Warrant as of Q1 2026.
Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.